Neonatal Bacille Calmette-Guérin Vaccination and Infections in the First Year of Life: The MIS BAIR Randomized Controlled Trial.

Nicole L Messina; Laure F Pittet; Kaya Gardiner; Bridget Freyne; Kate L Francis; Christel Zufferey; Veronica Abruzzo; Clare Morrison; Katrina J Allen; Katie L Flanagan; Anne-Louise Ponsonby; Roy Robins-Browne; Frank Shann; Mike South; Peter Vuillermin; Susan Donath; Dan Casalaz; Nigel Curtis

Journal article

Neonatal Bacille Calmette-Guérin Vaccination and Infections in the First Year of Life: The MIS BAIR Randomized Controlled Trial.

Nicole L Messina, Laure F Pittet, Kaya Gardiner, Bridget Freyne, Kate L Francis, Christel Zufferey, Veronica Abruzzo, Clare Morrison, Katrina J Allen, Katie L Flanagan, Anne-Louise Ponsonby, Roy Robins-Browne, Frank Shann, Mike South, Peter Vuillermin, Susan Donath, Dan Casalaz, Nigel Curtis

J Infect Dis | Published : 2021

DOI: 10.1093/infdis/jiab306

Abstract

BACKGROUND: Bacille Calmette-Guérin (BCG) vaccination has beneficial off-target effects that may include protecting against non-mycobacterial infectious diseases. We aimed to determine whether neonatal BCG vaccination reduces lower respiratory tract infections (LRTI) in infants in the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) trial. METHODS: In this investigator-blinded trial, neonates in Australia were randomized to receive BCG-Denmark vaccination or no BCG at birth. Episodes of LRTI were determined by symptoms reported in parent-completed, 3-month questionnaires over the first year of life. Data were analyzed by intention-to-treat using binary regression. R..

View full abstract